Yaojun Zhang

12.2k total citations · 3 hit papers
310 papers, 8.5k citations indexed

About

Yaojun Zhang is a scholar working on Hepatology, Oncology and Epidemiology. According to data from OpenAlex, Yaojun Zhang has authored 310 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Hepatology, 73 papers in Oncology and 63 papers in Epidemiology. Recurrent topics in Yaojun Zhang's work include Hepatocellular Carcinoma Treatment and Prognosis (129 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (51 papers) and Liver Disease Diagnosis and Treatment (47 papers). Yaojun Zhang is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (129 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (51 papers) and Liver Disease Diagnosis and Treatment (47 papers). Yaojun Zhang collaborates with scholars based in China, United States and Hong Kong. Yaojun Zhang's co-authors include Min-Shan Chen, Rong Guo, Zhenwei Peng, Li Xu, Pan Yang He, Minshan Chen, Wan Yee Lau, Hao Chen, Hui-Hong Liang and Li Cai Liu and has published in prestigious journals such as Cell, Physical Review Letters and Journal of Clinical Oncology.

In The Last Decade

Yaojun Zhang

297 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial

2012 369 citations Zhenwei Peng, Yaojun Zhang et al. Journal of Clinical Oncology profile →
Activatable fluorescent probes for real-time imaging-guided tumor therapy

2023 114 citations Yaojun Zhang et al. profile →
Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes

2024 63 citations Yaojun Zhang et al. profile →

Peers

Countries citing papers authored by Yaojun Zhang

Since Specialization

Citations

This map shows the geographic impact of Yaojun Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yaojun Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yaojun Zhang more than expected).

Fields of papers citing papers by Yaojun Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yaojun Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yaojun Zhang. The network helps show where Yaojun Zhang may publish in the future.

Co-authorship network of co-authors of Yaojun Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Yaojun Zhang. A scholar is included among the top collaborators of Yaojun Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yaojun Zhang. Yaojun Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA2 TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC) 2025 ·Annals of Oncology ·Jiahong Dong, (unknown), Satoshi Ogasawara, Ran Liu, Shanzhi Gu, Fang Liu, (unknown), Hao Hu, Zongwen Liu, Kezhi Lin, Junjie Liu, Zhenhua Lin, Yaojun Zhang, Tingting Peng, Junying Song, Makoto Ueno, Jie Zhu, Bai Li, Yang Shi, (unknown)	1
2	Comparing PD‐L1 and PD‐1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single‐center, real‐world study 2025 ·International Journal of Cancer ·(unknown), (unknown), (unknown), Jinbin Chen, Juncheng Wang, Yizhen Fu, Zili Hu, Meng Qi, Wenqing Gao, Dandan Hu, Yaojun Zhang, Yangxun Pan, Zhongguo Zhou	1
3	Serum S-adenosylhomocysteine, rather than homocysteine, is associated with hepatocellular carcinoma survival: a prospective cohort study 2024 ·American Journal of Clinical Nutrition ·(unknown), Siyu Huang, (unknown), (unknown), Aiping Fang, (unknown), (unknown), Chen Wang, Yaojun Zhang, Huilian Zhu	2
4	YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment 2024 ·Molecular Cancer ·(unknown), Xin Wang, Yizhen Fu, Weijie Wu, Zili Hu, Qingyang Lin, Wei Peng, Yangxun Pan, Juncheng Wang, Jinbin Chen, Dandan Hu, (unknown), Li Xu, Yaojun Zhang, Jiajie Hou, Minshan Chen	17
5	The CRAFITY score emerges as a paramount prognostic indicator in hepatocellular carcinoma patients received Lenvatinib and Pembrolizumab 2024 ·Frontiers in Immunology ·Weijie Wu, (unknown), Hao Zou, (unknown), Zhongguo Zhou, Yaojun Zhang, Minshan Chen, Dandan Hu	1
6	DNA of Neutrophil Extracellular Traps Binds TMCO6 to Impair CD8+ T-cell Immunity in Hepatocellular Carcinoma 2024 ·Cancer Research ·Mengjia Song, (unknown), Shaoyan Cheng, (unknown), (unknown), (unknown), Yaojun Zhang, (unknown), (unknown), (unknown), (unknown), (unknown), Tong Xiang, Yizhuo Zhang, Jian‐Chuan Xia	19
7	74P A single-center, phase II study of surufatinib combined with toripalimab, pemetrexed(A), and platinum (P) in patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC) 2023 ·Immuno-Oncology Technology ·Wenfeng Fang, Yunpeng Yang, Yan Huang, (unknown), Yaojun Zhang, Ting Zhou, (unknown), Shen Zhao, Yuxiang Ma, Shaodong Hong, Hongyun Zhao, Li Zhang	1
8	Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma 2023 ·Journal of Hepatocellular Carcinoma ·(unknown), (unknown), (unknown), Weijie Wu, (unknown), (unknown), Dandan Hu, Zhongguo Zhou, Minshan Chen, Yaojun Zhang	6
9	Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC) 2023 ·Clinical Cancer Research ·(unknown), (unknown), (unknown), ZhiCheng Lai, (unknown), JingXian Shen, (unknown), QiJiong Li, Yaojun Zhang, Wei Wei, MinShan Chen, Li Xu, Anna Kan, Ming Shi	17
10	Cholesterol Efflux Drives the Generation of Immunosuppressive Macrophages to Promote the Progression of Human Hepatocellular Carcinoma 2023 ·Cancer Immunology Research ·(unknown), Yongchun Wang, Rui Xing, (unknown), Xing-Juan Yu, Yaojun Zhang, Jing Xu, Limin Zheng	19
11	Prevalence of Non-Hodgkin Lymphoma Patients at High Risk of Failure after CAR T-Cell Therapy Eligible for Bridging Radiation Therapy 2023 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), (unknown), Karine A. Al Feghali, Lydia Pascual, Michael Marafelias, (unknown), André Goy, Tatyana Feldman, Yaojun Zhang, Scott D. Rowley, Andrew Ip	0
12	Systemic Inflammation Score Using Pretherapeutic Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy 2023 ·Journal of Hepatocellular Carcinoma ·(unknown), (unknown), Jiongliang Wang, (unknown), Juncheng Wang, Yangxun Pan, Jinbin Chen, Dandan Hu, Yaojun Zhang, Li Xu, Minshan Chen, Zhongguo Zhou	3
13	945MO AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC) 2023 ·Annals of Oncology ·Zefang Ren, Yuhua Huang, (unknown), Ming‐Mo Hou, Wei Wang, Ming Kuang, Hao Chen, Yaojun Zhang, Tianqiang Song, (unknown), (unknown), Victor Li, (unknown), Lei Wang, Jun Fan	10
14	Efficacy of additional locoregional therapy based on systemic therapy after intrahepatic progression for BCLC stage B/C hepatocellular carcinoma: A real-world study 2023 ·International Immunopharmacology ·Zili Hu, (unknown), (unknown), Weijie Wu, Zhongguo Zhou, Minshan Chen, Yizhen Fu, Yaojun Zhang	2
15	A 1.041-Mb/mm² 27.38-TOPS/W Signed-INT8 Dynamic-Logic-Based ADC-less SRAM Compute-in-Memory Macro in 28nm with Reconfigurable Bitwise Operation for AI and Embedded Applications 2022 ·2022 IEEE International Solid- State Circuits Conference (ISSCC) ·Bonan Yan, (unknown), (unknown), Chia‐Chi Lee, Yaojun Zhang, (unknown), (unknown), Yuchao Yang, Yue Yang, Hai Li, Yiran Chen, Ru Huang	89
16	Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma 2022 ·Journal of Inflammation Research ·(unknown), (unknown), (unknown), Yizhen Fu, Zili Hu, Yangxun Pan, Jinbin Chen, Juncheng Wang, Yaojun Zhang, Zhongguo Zhou, Li Xu, Dandan Hu, Minshan Chen	20
17	PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma 2022 ·Cancer Research ·(unknown), Dong‐Ping Chen, Shi‐Xun Lu, Jinbin Chen, Wei Yuan, Xuechao Liu, Yuhao Tang, (unknown), Jiancong Chen, Anna Kan, Li Xu, Yaojun Zhang, Jiajie Hou, Dong‐Ming Kuang, Minshan Chen, Zhongguo Zhou	12
18	Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients 2020 ·Cancer Communications ·Zhongguo Zhou, Jinbin Chen, Rongxin Zhang, (unknown), Juncheng Wang, Yangxun Pan, Xiaohui Wang, (unknown), Yaojun Zhang, Li Xu, Minshan Chen	12
19	Single versus multiple port laparoscopic left lateral sectionectomy for hepatocellular carcinoma: A retrospective comparative study 2020 ·International Journal of Surgery ·(unknown), Yangxun Pan, Jinbin Chen, Dandan Hu, (unknown), Zhongguo Zhou, Li Xu, Jiancong Chen, Minshan Chen, Yaojun Zhang	2
20	Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial breakdown → 2012 ·Journal of Clinical Oncology ·Zhenwei Peng, Yaojun Zhang, Min-Shan Chen, Li Xu, Hui-Hong Liang, Xiao-Jun Lin, Rong Guo, Ya-Qi Zhang, Wan Yee Lau	369

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact